Prognostic factors and survival in node-positive (N1) prostate cancer -: A prospective study based on data from a Swedish population-based cohort

被引:25
作者
Aus, G [1 ]
Nordenskjöld, K
Robinson, D
Rosell, J
Varenhorst, E
机构
[1] Sahlgrens Univ Hosp, Dept Urol, S-41345 Gothenburg, Sweden
[2] Linkoping Univ Hosp, Onkol Centrum, S-58185 Linkoping, Sweden
[3] Hoglandssjukhuset, Dept Surg, Eksjo, Sweden
[4] Vrinnevisjukhuset, Dept Urol & Surg, Norrkoping, Sweden
关键词
prostate cancer; lymph node metastasis; N-category; prognosis; risk factors; treatment;
D O I
10.1016/S0302-2838(03)00156-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: At presentation of prostate cancer, patients with proven lymph node metastasis (NI) are comparatively rare. It is difficult to give prognostic information based on the present literature. The aim of this study was to evaluate the impact of known risk factors in patients with pelvic node involvement and without distant metastasis. Methods: From the population-based, prospective prostate cancer tumour registry of the South-East Region in Sweden, we collected data on all 181 patients with NI, MO prostate cancer diagnosed from January 1987 to October 2000 with a follow-up to December 2001. Mean follow-up was 62 months. Pre-operative risk factors as age, T-category, serum PSA, tumour grade and also primary treatment given was correlated to the outcome. Results: Median age at diagnosis was 65 years. Cancer-specific survival was highly variable with 5-year survival of 72%, a median of 8 years and the projected 13-year figure was 31%. T-category, age, PSA or treatment did not affect the outcome while poorly differentiated tumours had a tendency towards lower cancer-specific survival (p = 0.0523) when compared to well and moderately differentiated tumours. Conclusions: This population-based cohort of prostate cancer patients with pelvic node involvement treated principally with non-curative intent had a median cancer-specific survival of 8 years. Preoperatively known risk factors seem to have but a modest impact on the prognosis for patients in this stage of the disease. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:627 / 631
页数:5
相关论文
共 17 条
[11]   Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer [J].
Robnett, TJ ;
Whittington, R ;
Malkowicz, SB ;
Brereton, HD ;
Van Arsdalen, K ;
Drach, G ;
Wein, AJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (05) :1146-1151
[12]   Prostate-specific antigen for prostate cancer staging in a population-based register [J].
Sandblom, G ;
Holmberg, L ;
Damber, JE ;
Hugosson, J ;
Johansson, JE ;
Lundgren, R ;
Mattsson, E ;
Nilsson, J ;
Varenhorst, E .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2002, 36 (02) :99-105
[13]   INFLUENCE OF RADIOTHERAPY ON NODE-POSITIVE PROSTATE-CANCER TREATED WITH ANDROGEN ABLATION [J].
SANDS, ME ;
POLLACK, A ;
ZAGARS, GK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (01) :13-19
[14]   Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation [J].
Seay, TM ;
Blute, ML ;
Zincke, H .
JOURNAL OF UROLOGY, 1998, 159 (02) :357-364
[15]   IMPLICATIONS OF VOLUME OF NODAL METASTASIS IN PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE [J].
SMITH, JA ;
MIDDLETON, RG .
JOURNAL OF UROLOGY, 1985, 133 (04) :617-619
[16]   EARLY ANDROGEN ABLATION FOR STAGE D1 (N1 TO N3, M0) PROSTATE-CANCER - PROGNOSTIC VARIABLES AND OUTCOME [J].
ZAGARS, GK ;
SANDS, ME ;
POLLACK, A ;
VONESCHENBACH, AC .
JOURNAL OF UROLOGY, 1994, 151 (05) :1330-1333
[17]   Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer [J].
Zagars, GK ;
Pollack, A ;
von Eschenbach, AC .
UROLOGY, 2001, 58 (02) :233-239